Endocrine Surgical Oncology Lab

Early Detection, Novel Therapies, and a Better Understanding of Endocrine Cancers

Our work focuses on the genetic and epigenetic abnormalities in endocrine tumors. Understanding their origin and development  will lead to better strategies for early detection of endocrine cancers and  therapeutic targets.

Current areas of investigation include:

  1. Identification and clinical validation of thyroid cancer biomarkers that could lead to early detection and better prognostication,
  2. Molecular classification and mechanism of dysregulated genes in malignant adrenal tumors,
  3. Novel therapeutic approaches to treat thyroid or adrenal cancer subpopulations that do not respond well to current conventional therapeutic strategies
  4. Molecular basis of gender and ethnic disparity in thyroid cancer incidence.

Recent Publications

Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH
Defining a molecular phenotype for benign and malignant parathyroid tumors.
Cancer, Jan-15-2009; 1152: 334-44.
Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E
Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
Surgery, Dec-01-2008; 1446: 908-13; discussion 913-4.
Shibru D, Hwang J, Khanafshar E, Duh QY, Clark OH, Kebebew E
Does the 3-gene diagnostic assay accurately distinguish benign from malignant thyroid neoplasms?.
Cancer, Sep-01-2008; 1135: 930-5.
Fernandez-Ranvier GG, Weng J, Yeh RF, Khanafshar E, Suh I, Barker C, Duh QY, Clark OH, Kebebew E
Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling.
Archives of surgery (Chicago, Ill. : 1960), Sep-01-2008; 1439: 841-6; discussion 846.
Fernandez-Ranvier GG, Weng J, Yeh RF, Shibru D, Khafnashar E, Chung KW, Hwang J, Duh QY, Clark OH, Kebebew E
Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13.
World journal of surgery, May-01-2008; 325: 873-81.
Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A
The prevalence and prognostic value of BRAF mutation in thyroid cancer.
Annals of surgery, Sep-01-2007; 2463: 466-70; discussion 470-1.
Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, Werb Z, Clark OH
Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
Endocrine-related cancer, Dec-01-2006; 134: 1173-83.
Kebebew E, Peng M, Reiff E, Duh QY, Clark OH, McMillan A
Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms.
World journal of surgery, May-01-2006; 305: 767-74.
Shen WT, Wong TS, Chung WY, Wong MG, Kebebew E, Duh QY, Clark OH
Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Surgery, Dec-01-2005; 1386: 979-84; discussion 984-5.
Marsee DK, Vadysirisack DD, Morrison CD, Prasad ML, Eng C, Duh QY, Rauen KA, Kloos RT, Jhiang SM
Variable expression of coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy.
Thyroid : official journal of the American Thyroid Association, Sep-01-2005; 159: 977-87.
View all Publications »

News and Events

View all News»